Epidemiology of breast cancer

Epidemiology

  • In U.S., most common cancer in women; 2nd leading cause of cancer death in women

  • Genetic risk: 15–20% ⊕ FHx → 2× ↑ risk; ~45% familial cases a/w germline mutation. BRCA1/2: 35–85% lifetime risk of breast ca. Germline loss-of-function mutations in PALB2 a/w 35% ↑ risk breast cancer by age 70. Moderate risk mutations CHEK2 and BARD1 a/w 15–30% lifetime risk of breast cancer (NEJM 2021;384:428).

  • Estrogen: ↑ risk with early menarche, late menopause, late parity or nulliparity (NEJM 2006;354:270); ↑ risk with prolonged HRT (RR = 1.24 after 5.6 y; JAMA 2003;289:3243); OCP use a/w extremely low to no ↑ risk (NEJM 2017:317:2228; JAMA Oncol 2018;4:516)

參考➡️ Estrogen carcinogenesis in breast cancer

estrogen-receptor–signaling pathways

  • Benign breast conditions: ↑ risk if atypia (atypical ductal or lobular hyperplasia; NEJM 2015;372:78) or proliferative (ductal hyperplasia, papilloma, radial scar, or sclerosing adenosis) features; no ↑ risk w/ cysts, simple fibroadenoma, or columnar changes
  • ↑ risk with h/o ionizing radiation to chest for treatment of Hodgkin lymphoma

prevention of breast cancer